PACB logo

PACIFIC BIOSCIENCES OF CALIF

PACBNASDAQ
πŸ† #2481 by market capEarnings Nov 4 Β· PostUS Equity
$2.91β–² $0.09 (+3.19%)
Pre-market Β· at close
πŸ””
Track PACB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.2%
7dβ–² 37.9%
14dβ–² 67.7%
30dβ–² 23.3%
ytdβ–² 54.8%
1yβ–² 50.0%
🏦Market Cap
$905M
Small Cap
πŸ“ˆRevenue Growth (YoY)
2.0%
Slowing
πŸ“ŠGross Margin
39.2%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
4.8x
Fair
Otter Score
60
Fair

Trading Snapshot

Day Range
$2.77 – $2.96
52-Week Range
$1.07 – $3.44
Volume (shares)
954,639
Avg Volume (shares)
β€”
Shares Outstanding
310.8M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$160M
Last Q Revenue
$39M
P/E Ratio
β€”
P/S Ratio
4.8x
EPS (TTM)
$-0.43
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.6%
PACB logo

PACIFIC BIOSCIENCES OF CALIF

PACB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$160Mβ–² +3.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
31.7%β–² +30.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$558Mβ–² +17.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$114Mβ–Ό βˆ’46.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
301.9Mβ–Ό βˆ’1.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$696Mβ–Ό βˆ’$79M YoY
StockOtter Β· stockotter.space

About PACIFIC BIOSCIENCES OF CALIF

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Ratings

β“˜
Consensus
Buy
14 analysts
Strong Buy4
Buy5
Hold4
Sell1
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.